EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
EYPT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$4.95M, compared with $3.43M a year earlier. Trailing-twelve-month accounts receivables was -$19.05M. Over 3 fiscal years it compounded at +58.8% a year.
Context
- Accounts receivables amounted to 34.0% of revenue in FY2025, up 33.4 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$4.95M or moves back toward the trailing-twelve-month quarterly average of -$4.76M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (10.67M) USD
- Year-over-year change
- -4271.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.67M) | -4271.7% |
| FY2024 | 2024-12-31 | (244K) | -101.7% |
| FY2023 | 2023-12-31 | 14.43M | +642.1% |
| FY2022 | 2022-12-31 | (2.66M) | +74.9% |
| FY2021 | 2021-12-31 | (10.6M) | — |
Accounts Receivables vs competitors
How EYPT compares with its peers on the latest reported figures
- EYPT's LTM Mar 2026 accounts receivables of $19.05M is the 2nd largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of -355.9% is the lowest of 5, against a peer median of +192.2%.
- Accounts receivables amounts to 250.2% of revenue for EYPT, versus a peer median of 10.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $39.4M | +184.4% | — | 55.0% | |
| LTM Mar 2026 | $19.05M | -355.9% | +58.8% | 250.2% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $10.24M | +21.4% | — | 10.6% |
| LTM Mar 2026 | $720K | +373.7% | — | 81.0% | |
| LTM Mar 2026 | $17K | +200.0% | — | 0.4% | |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Aug 2026 | $0 | — | — | 0.0% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding EYPT) | $0 | +192.2% | — | 10.6% | |
Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.42M) | (102.25M) | (70.8M) | (130.87M) | (231.96M) |
| Depreciation & Amortization | 2.77M | 2.45M | 464K | 1.54M | 2.31M |
| Deferred Income Tax | (787K) | 0 | 83K | 90K | 279K |
| Stock-Based Compensation | 7.45M | 14.18M | 12.06M | 36.74M | 27.87M |
| Change in Working Capital | (1.74M) | (3.02M) | 58.88M | (27.77M) | (33.78M) |
| Accounts Receivables | (10.6M) | (2.66M) | 14.43M | (244K) | (10.67M) |
| Inventory | 1.35M | (760K) | (1.55M) | 1.6M | 492K |
| Accounts Payables | 8.48M | 1.2M | 1.52M | 5.73M | 4.68M |
| Other Working Capital | (959K) | (799K) | 44.48M | (34.86M) | (28.28M) |
| Other Non-Cash Items | 628K | 23.65M | 1.18M | (5.95M) | (4.83M) |
| Operating Cash Flow | (50.1M) | (65.01M) | 1.88M | (126.23M) | (240.11M) |
| Capital Expenditures | (156K) | (2.15M) | (3.48M) | (4.05M) | (3.28M) |
| Acquisitions (Net) | 0 | (558K) | (168K) | 0 | 155K |
| Purchases of Investments | (32.97M) | (139.12M) | (55.12M) | (398.3M) | (252.02M) |
| Sales of Investments | 0 | 124M | 55.28M | 177.05M | 318.9M |
| Other Investing Activities | 0 | 558K | 168K | 5.95M | 4.83M |
| Investing Cash Flow | (33.12M) | (17.27M) | (3.32M) | (219.36M) | 68.58M |
| Debt Repayment | (146K) | 2.1M | (40.51M) | (105K) | (105K) |
| Common Stock Issued | 216.83M | 395K | 226.17M | 163.31M | 175.14M |
| Common Stock Repurchased | 0 | (295K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 223K | (3.19M) | 1.41M | 813K | (1.39M) |
| Financing Cash Flow | 216.9M | (690K) | 187.07M | 164.02M | 173.65M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 133.68M | (82.96M) | 185.63M | (181.56M) | 2.12M |
| Free Cash Flow | (50.25M) | (67.16M) | (1.61M) | (130.28M) | (243.39M) |
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.